Combined Treatment for Generalized Anxiety Disorder (GAD)

PHASE2CompletedINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

March 31, 2008

Study Completion Date

March 31, 2008

Conditions
Generalized Anxiety Disorder
Interventions
BEHAVIORAL

Cognitive Behavioral Therapy

This cognitive behavioral therapy for GAD has a cognitive restructuring component and an applied relaxation component. Patients will be educated about the nature of anxiety and be trained in the recognition and monitoring of situational, physiological, cognitive, and behavioral cues associated with anxious responding. They will be guided through copings skill rehearsals in addition to imaginal and in vivo exposure to anxiety cues. This cognitive behavioral treatment will consist of 1 to 1.5 hour sessions of psychotherapy, which will be held once weekly over a period of 12 weeks.

DRUG

Venlafaxine XR

Venlafaxine XR, 75-225 mg/d, oral administration. 14 days at 75 mg/d, 150 mg/d for the remaining 6 months, 225 mg/3 for patients unimproved at week 6, tapered at 75 mg/week (this intervention is provided by protocol 709012).

Trial Locations (1)

19104

University of Pennsylvania, 3535 Market Street, Suite 650, Philadelphia

All Listed Sponsors
collaborator

National Institute of Mental Health (NIMH)

NIH

lead

University of Pennsylvania

OTHER

NCT00620776 - Combined Treatment for Generalized Anxiety Disorder (GAD) | Biotech Hunter | Biotech Hunter